Author's Reply to Joerg Putzke et al. Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".
Jingjing QianCong Bang TruongKaniz Afroz TanniPublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2021)